Clinical and Microbiological Aspects of Probiotics in Non-surgical Periodontal Therapy.

September 30, 2023 updated by: Prof. Marco Dolci, G. d'Annunzio University

Clinical and Microbiological Aspects of Probiotics in Non-surgical Periodontal Therapy: a Randomized Controlled Trial.

The goal of this randomized clinical trial is to test the effect orally administration of Probiotics based on Lactobacillus rhamnosus LR04 and Lactobacillus plantarum LP14 as adjuvant in people suffering from periodontitis stage II-III. The main questions it aims to answer are:

  • QUESTION 1: orally administered probiotics based on the previous strains could represent a useful tool in support of non-surgical periodontal therapy in reducing clinical periodontal indexes?
  • QUESTION 2: orally administered probiotics based on the previous strains could represent a useful tool in support of non-surgical periodontal therapy in reduce the amount of periodontal pathogens in periodontal pockets?

Partecipants in the test group will take the test probiotic for 90 days in adjunction of the routinary oral hygiene procedures.

Partecipants in the positive controlled group will take the placebo for 90 days in adjunction of the routinary oral hygiene procedures.

Partecipants in the negative control group will perform only the routinary oral hygiene procedures.

Researchers will compare 3 groups to see if orally administered probiotics based on L. rhamnosus and L. plantarum may hel in the reduction of periodontal indexes and of the periodontal pathogen bacteria.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

The diagnosis of periodontitis passes through the recording of periodontal probing values on 6 sites for each periodontal element, the recording of clinical indices such as the percentage of bleeding sites and those with plaque, finally through the execution of a full-x-ray consisting of intraoral films that guarantee staging through the calculation of the loss of clinical attachment, corresponding to the loss of alveolar bone caused by the disease. The therapy of periodontitis is composed of several steps and begins with the control of the biofilm. This control is carried out with professional supragingival hygiene sessions followed by subgingival instrumentation of the periodontal pockets in order to remove the hard and soft deposits below the gingival margin, which would not otherwise be eliminated with the supragingival strategy alone. The response to mechanical therapy and the risk of relapses go hand in hand with the patient's response, his ability to maintain a good level of oral hygiene at home and to keep return appointments. In this sense, dental research has worked hard to develop additional aids to mechanical therapy to try to improve its performance. In the last decade in particular, the use of probiotics has found an increasingly wider field in periodontology, as they are based on the idea of enhancing the eubiosis ratios of the non-pathogenic flora in order to make the environment unfavorable for the proliferation of a pathogenic flora.

The present study aims to evaluate whether the quarterly oral administration of probiotics based on Lactobacillus plantarum LP14 and Lactobacillus rhamnosus LR04 can improve the response to non-surgical periodontal therapy of subgingival instrumentation in patients suffering from stage II-III periodontitis and complexity of grade A-B.

Primary objective To evaluate the adjuvant effect of probiotics based on Lactobacillus plantarum LP14 and Lactobacillus rhamnosus LR04 in non-surgical periodontal therapy.

Secondary objective Characterize the microbiological picture of patients with periodontitis with and without the aid of probiotics.

MATERIALS AND METHODS Three groups of volunteers of both sexes will be enrolled for the study without age restrictions.

Inclusion criteria Patients in the absence of other systemic pathologies reported in the medical history, smokers and non-smokers, non-drinkers, in the absence of previous or current administration of other sources of probiotics, capable of providing informed consent.

Exclusion criteria Subjects with a history of systemic diseases (diabetes, autoimmune diseases, inflammatory bowel diseases, neurodegenerative diseases), drinkers, who take or have taken probiotics in the last 3 months, unable to provide informed consent.

Minimum sample size Sample size calculation (Alpha = 0.05; Power = 95%) for 3 independent study groups, and a continuous primary endpoint. Sample size = Z2 (1-alpha/2) p (1-p) / d2 Where Z(1-alpha/2) is the standard variate corresponding to 1.96 at 5% type 1 error, p is the expected proportion in the population expressed in decimals based on previous studies and d is the confidence level decided by the researcher expressed in decimal. Regarding the primary outcome of Bleeding On Probing (BOP), the expected difference between the means was assumed to be 20%, therefore 20 patients per group are required, for a total of 60 patients. To these patients, the dropout percentage of 10% must be added, so the total is 70 patients.

T0 - BASELINE The first dental visit and the treatment plan will be carried out by Prof. Marco Dolci. The periodontal visit with the registration of the indices and the full-rx will be carried out by Prof. Marco Dolci.

Clinical indixes

  • Bleeding On Probing - BOP, percentage value on 6 sites for each tooth
  • Pocket Probing Depth - PPD on 6 sites for each tooth
  • Clinical Attachment Loss - CAL on intraoral radiographs of pathological sites
  • Plaque Index - PI, rated from 0 to 4 for each site
  • Percentage of pathological sites out of total sites. The recording of BOP, PPD, PI will be carried out through periodontal probing using the PCP-15 UNC periodontal probe (HuFriedi) in a completely atraumatic and non-invasive manner.

The operational session will be organized as follows:

  • Supragingival instrumentation with piezoelectric ultrasonic scaler handpiece;
  • BPA microbiological test (Bacterial Periodontal Assessment - Biomolecular Diagnostic, Via Nicola Porpora, 550144 - Florence) through sampling of the gingival crevicular fluid with a thin cone of sterile paper with a diameter of 0.3 mm positioned in the pocket for 60 seconds, in an atraumatic and non-traumatic manner invasive. After sampling, the cones will be inserted into a single test tube;
  • Subgingival instrumentation of periodontal pockets using Gracey curettes. The treatment is to be considered as Full Mouth Treatment (FMT). The samples will be transported to the laboratory located on the third floor of Building A, taken into custody by Prof. Marco Dolci and stored at + 4° C until the arrival of the dedicated courier.

The same Biomolecular Diagnostic company will take care of collecting the samples via dedicated biological courier and will carry out the PCR analyzes in its laboratories.

At the end of the analyses, a copy of a unique identification code will be sent to the Experimenters so that they can access the report.

Placement of the patient in the test, positive and negative control groups

TEST: home oral hygiene 2/day with soft bristle toothbrush + standard fluoride toothpaste + probiotic in buccal sachet to be consumed once a day until the quarterly check-up.

POSITIVE CONTROL: home oral hygiene 2/day with soft bristle toothbrush + standard fluoride toothpaste + industrial placebo in buccal sachet to be consumed once a day until the quarterly check-up.

NEGATIVE CONTROL: home oral hygiene 2/day with soft bristle toothbrush + standard fluoride toothpaste.

The products (test and placebo) will be delivered to the patient at the end of the session in order to cover 3 months of administration.

T1 - AFTER 3 MONTHS FROM T0

  • Recording of periodontal indices.
  • Microbiological samples.

Randomization The treatment that is due to the individual patient is kept in sequentially numbered, opaque and sealed envelopes (SNOSE Sequentially Numbered, Opaque, Sealed Envelopes). The products used for both the test and the controls will be supplied in anonymous tubes so that neither the patient nor the investigator will be aware of them.

Statistical analysis Proper statistical analysiswill be perfomed by the trusted statistical group.

Study Type

Interventional

Enrollment (Estimated)

70

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • Italy
      • Chieti, Italy, 66100
        • University G. d'Annunzio
        • Contact:
        • Principal Investigator:
          • Marco Dolci, MD DDS PHD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Patients in the absence of other systemic pathologies reported in the medical history
  • smokers and non-smokers, non-drinkers,
  • subjects in the absence of previous or current administration of other sources of probiotics,
  • subjects capable of providing informed consent.

Exclusion Criteria:

  • Subjects with a history of systemic diseases (diabetes, autoimmune diseases, inflammatory bowel diseases, neurodegenerative diseases),
  • drinkers,
  • subjects who take or have taken probiotics in the last 3 months,
  • subjects unable to provide informed consent.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Probiotics
Patients who will be assigned to oral consumption of one stick of probiotics with L. plantarum and L. rhamnosus for 30 days, in adjucntion to routinary oral hygiene procedures.
Other: Experimental
Orally administred probiotics with L. plantarum and L. rhamnosus
Other Names:
  • Orally administration of probiotics with L. plantarum and L. rhamnosus
Placebo Comparator: Positive Control
Patients who will be assigned to oral consumption of one stick of placebo for 30 days, in adjucntion to routinary oral hygiene procedures.
Other: Positive control
Orally administred placebo without probiotics
Other Names:
  • Orally administred placebo without probiotics
Other: Negative control
Patients who will be assigned to routinary oral hygiene procedures esclusively.
Other: Negative control
Only routinary oral hygiene procedures
Other Names:
  • Only routinary oral hygiene procedures

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Reduction of clinical periodontal indexes
Time Frame: From enrollement to the end of treatment at 3 months.
Evaluation of clinical periodontal indexes, such as: bleeding on probing (BOP), periodontal pocket depth (PPD), clinical attachment level (CAL), plaque index (PI), total number of pathological sites in %.
From enrollement to the end of treatment at 3 months.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Reduction of periodontal pathogen bacteria amount.
Time Frame: From enrollement to the end of treatment at 3 months.
Evaluation of the amount of periodontal pathogen bacteria such as: A. actinomycetemcomitans, P. gingivalis, P. intermedia and F. nucleatum
From enrollement to the end of treatment at 3 months.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

G. d'Annunzio University

Collaborators

Probiotical S.p.A.

Investigators

  • Principal Investigator: Marco Dolci, MD DDS PHD, University G. d'Annunzio of Chieti

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

October 1, 2023

Primary Completion (Estimated)

March 1, 2024

Study Completion (Estimated)

June 1, 2024

Study Registration Dates

First Submitted

September 26, 2023

First Submitted That Met QC Criteria

September 26, 2023

First Posted (Actual)

October 2, 2023

Study Record Updates

Last Update Posted (Actual)

October 4, 2023

Last Update Submitted That Met QC Criteria

September 30, 2023

Last Verified

September 1, 2023

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • PARO

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

A decision regarding IPD sharing has not been made yet because a dedicated website is not available at the momente.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Periodontitis

Clinical Trials on Experimental

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Slovakia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe